Secukinumab two weekly versus four weekly dosing in patients with plaque-type psoriasis: results from the randomized GAIN study.

CONCLUSIONS: Most patients achieved PASI90 response with secukinumab q4w. There was potential benefit of q2w dosing in some suboptimal responders. Continued q4w treatment can improve response even after 16 weeks. PMID: 32652528 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32652528?dopt=Abstract

Source: The British Journal of Dermatology - July 10, 2020 Category: Dermatology Authors: Reich K, Körber A, Mrowietz U, Sticherling M, Sieder C, Früh J, Bachhuber T Tags: Br J Dermatol Source Type: research